Apremilast,
does it really help with PASI 75 and static Physician Global Assessment improvement in moderate-to-severe plaque psoriasis?
research showsApremilast increased week-16 PASI 75 responses over placebo in both ESTEEM trials, and response was observed in competitor-sponsored trials, but the graded evidence concerns PASI 75 and static Physician Global Assessment surrogate measures rather than a patient-experienced event, yielding C. ESTEEM 1 analyzed all 844 randomized participants and found 33.1% versus 5.3%; ESTEEM 2 used a full-analysis set of 411 and found 28.8% versus 5.8%. Apremilast PASI 75 was 35.1% in POETYK PSO-1. ESTEEM was sponsored by Celgene and POETYK by Bristol Myers Squibb; no publicly or noncommercially funded independent confirmation was identified, giving I0 and C with 55 points.
ads claimMarketing can turn an oral-drug response rate into an implication of complete clearance for everyone or efficacy matching leading biologics. Actual week-16 PASI 75 response was about 29% to 40% and did not mean complete clearance.
Useful facts when choosing a product
- The ESTEEM apremilast regimen was 30 mg twice daily, with a 16-week placebo-controlled phase followed by longer phases.
- Verdict 1796, which is C with 55 points, concerns deucravacitinib; POETYK PSO-1 found PASI 75 of 58.4% versus 35.1% with apremilast. Verdict 1342, which is B with 76 points, concerns secukinumab; verdict 1815, which is C with 58 points, concerns guselkumab; and verdict 1814, which is C with 58 points, concerns home narrowband UV-B. Across these five plaque-psoriasis verdicts, PASI-family lesion scales alone receive the same S-to-C ceiling; a different grade requires additional patient-centered or hard-endpoint structure.
- Apremilast is an oral prescription PDE4 inhibitor. PASI 75 denotes at least a 75% reduction from baseline PASI; this measurement definition is separate from the clinical-evidence grade.
What the research actually shows
ESTEEM 1 randomized 844 participants two to one and analyzed a full-analysis set of 844; week-16 PASI 75 was 33.1% versus 5.3%, P<0.0001, meeting the primary endpoint. ESTEEM 2 randomized 413 and analyzed 411, with 28.8% versus 5.8%, P<0.001, also meeting the primary endpoint. Both were sponsored by Celgene. Bristol Myers Squibb-sponsored POETYK PSO-1 randomized 666, including 168 assigned to apremilast; week-16 PASI 75 was 35.1% and static Physician Global Assessment 0 or 1 was 32.1%. Among 254 apremilast participants in PSO-2, PASI 75 was 40.2%. POETYK compared the sponsor's deucravacitinib with placebo and apremilast, so it is not public or nonprofit independent replication.
Why this is classified as C (55)
Concordant ESTEEM and POETYK results support R2, but Celgene and competitor-sponsored Bristol Myers Squibb trials do not provide public or nonprofit independent confirmation, giving I0. PASI 75 and static Physician Global Assessment remain surrogate S endpoints, so the result is C with 55 points.
Counterpoint. Headache, diarrhea, nausea, weight loss, and mood symptoms require consideration. Patients seeking higher clearance or those with joint disease should compare other systemic options.
Rejudgment record. Cross-check applied — PASI 75 succeeded in multiple manufacturer-sponsored randomized trials, but no public or nonprofit independently funded confirmation was identified and the PASI 75 and static Physician Global Assessment surrogate ceiling applies to S, R2, I0, E+, and B0
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R2 | Independently replicated across trials |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Week-16 PASI 75 skin response | C | Multiple large randomized trials succeeded, but this is a surrogate endpoint. |
| Week-16 static Physician Global Assessment 0 or 1 response | C | The response was positive in ESTEEM and POETYK but remains an investigator-rated lesion scale. |
| Superior lesion improvement versus another oral systemic treatment | D | Apremilast was inferior to deucravacitinib in POETYK. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Papp K et al. 2015 ESTEEM 1 | Phase 3 randomized double-blind placebo-controlled trial | 282 | Manufacturer-sponsored, designed, and analyzed by Celgene Corporation | PASI 75 response at week 16 | 33.1% versus 5.3%, P<0.0001; the primary endpoint succeeded. | Pivotal large registration trial |
| Paul C et al. 2015 ESTEEM 2 | Phase 3 randomized double-blind placebo-controlled trial | 137 | Manufacturer-sponsored by Celgene Corporation | PASI 75 response at week 16 | 28.8% versus 5.8%, P<0.001; the primary endpoint succeeded. | Within-manufacturer confirmatory replication |
| Armstrong AW et al. 2023 POETYK PSO-1 | Phase 3 randomized double-blind placebo- and active-controlled trial | 168 | Sponsored by Bristol Myers Squibb, a competitor rather than the apremilast manufacturer | Co-primary PASI 75 and static Physician Global Assessment 0 or 1; apremilast active-control performance | Apremilast PASI 75 was 35.1% and static Physician Global Assessment 0 or 1 was 32.1%, below 58.4% and 53.6% with deucravacitinib. | Competitor-sponsored active-control data, not public or nonprofit independent replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Apremilast x lesion improvement in moderate-to-severe plaque psoriasis — Evidence Grade C·55. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/apremilast-moderate-severe-plaque-psoriasis-clearance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.